Business
Odyssey Group International to Present at LD Micro Virtual Investor Conference
Odyssey Group International to Present at LD Micro Virtual Investor Conference.
About this update from Odyssey Health Inc.
[{"type":"text","content":"\n IRVINE, CA, June 08, 2021 (GLOBE NEWSWIRE) -- Odyssey Group International, Inc. (OTCQB: ODYY) (the \"Company\" or \"Odyssey\"), a technology and asset acquisition company focused on developing unique, life-saving medical products, announced today that its CEO, Michael Redmond, and Executive VP of Drug Development, Dr. Jake VanLandingham will present at the 2021 LD Micro Invitational XI Investor Conference. Presentation details: Date: Thursday, June 10, 2020Time: 11:00-11:30am EDTInvestors can register for the conference HERE. Management will provide an overview of the Company's strategy in developing and acquiring life-saving medical products, including its drug candidate PRV-002, a novel neurosteroid being developed for the treatment of concussion (mild traumatic brain injury) (mTBI). About Odyssey Group International, Inc.Odyssey Group International, Inc. (OTCQB: ODYY) is a technology and asset acquisition company with a focus in the area of life-saving medical solutions. Odyssey's corporate mission is to create, acquire and accumulate distinct assets, intellectual properties, and exceptional technologies that provide meaningful medical solutions. The Company is focused on building and acquiring assets in areas that have an identified technological advantage, provide superior clinical utility, have a substantial market opportunity and provide solid returns to its valued shareholders and partners. For more information, visit: http://www.odysseygi.com About PRV-002PRV-002 is a fully synthetic non-naturally occurring neurosteroid being developed for the treatment of mTBI (concussion). In preclinical studies, PRV-002 has demonstrated equivalent, if not superior, neuroprotective effects compared to related neurosteroids. Animal models of concussion demonstrated that PRV-002 reduces the behavioral pathology associated with brain injury symptoms such as memory impairment, anxiety, and motor/sensory performance. Additionally, PRV-002 is lipophilic and can easily cross the blood-brain barrier to rapidly eliminate swelling, oxidative stress and inflammation in the brain while restoring proper blood flow. Forward-Looking StatementsThis news release may contain forward-looking statements within the meaning of the \"safe harbor\" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based...